Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMPR2 | Q13873 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 6/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4137916 | 0.90 | MAPT (0.46) | RORCRPS6KB1SIRT2SIRT1TP53 | |
| SCHEMBL4122881 | 0.90 | L3MBTL1 (0.48) | BMPR2RORCTP53L3MBTL1 | |
| SCHEMBL4518317 | 0.87 | RPS6KB1 (0.42) | RPS6KB1SIRT2SIRT1TP53MAPT | |
| SCHEMBL4140385 | 0.86 | RPS6KB1 (0.40) | RPS6KB1SIRT2SIRT1TP53MAPT | |
| SCHEMBL5776100 | 0.85 | SIRT2 (0.45) | RPS6KB1SIRT2SIRT1TP53MAPT | |
| SCHEMBL4123368 | 0.84 | L3MBTL1 (0.51) | RPS6KB1SIRT2SIRT1TP53MAPT | |
| SCHEMBL4140386 | 0.84 | SIRT2 (0.42) | RPS6KB1SIRT2SIRT1TP53MAPT | |
| SCHEMBL4124652 | 0.83 | SIRT2 (0.42) | RPS6KB1SIRT2SIRT1TP53MAPT | |
| SCHEMBL4118974 | 0.82 | RPS6KB1 (0.44) | BMPR2RPS6KB1SIRT2SIRT1TP53 | |
| SCHEMBL4124971 | 0.82 | L3MBTL1 (0.48) | RPS6KB1SIRT2SIRT1TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511145-B2 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20090081165-A1 | BICYCLIC HETEROARYL DERIVATIVES | GENELABS TECHNOLOGIES, INC. | 2009-03-26 | — | — | US | disclosed |
| EP-1651631-A1 | BICYCLIC IMIDAZOL DERIVATIVES AGAINST FLAVIVIRIDAE | GENELABS TECHNOLOGIES, INC. (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. | 2005-08-25 | — | — | US | disclosed |
| WO-2005012288-A1 | BICYCLIC IMIDAZOL DERIVATIVES AGAINST FLAVIVIRIDAE | GENELABS TECHNOLOGIES, INC (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090081165-A1 | BICYCLIC HETEROARYL DERIVATIVES | HAVCR2, MAVS, ZC3HAV1 | BMPR2 4096/4885CNR1 2567/4885RORC 439/4885 |
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | HAVCR2, MAVS, ZC3HAV1 | BMPR2 4096/4885CNR1 2567/4885RORC 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.